English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chagas disease, or American trypanosomiasis, is caused by the protozoan parasite Trypanosoma cruzi. It is a major cause of cardiac disease in the Americas. At least 6 million people are currently infected in Latin America, including 1 million women of reproductive age [1]. In the United States, the estimated number of T. cruzi-infected women of reproductive age was 130,522 in 2000 [2]. Healthcare costs of the disease amount to over US$24 billion [3]. Treatment options for infected patients are limited, with only two drugs available (Benznidazole and Nifurtimox), and require prolonged treatments, which have limited efficacy and important adverse effects [4]. New treatments are therefore needed to improve patient care [5].

plos neglected tropical diseases

A therapeutic preconceptional vaccine against Chagas disease: A novel indication that could reduce congenital transmission and accelerate vaccine development